Content by BellBrook Labs

Polypharmacology allows scientists to explore novel therapeutic purposes for existing drugs and opens new doors to treat multifactorial diseases.

An overview of the Transcreener ADPR assay

A guide to biochemical assays for measuring drug-target interactions

The Transcreener dAMP Exonuclease Assay reliably locates compounds that antagonize TREX1.

Universal kinase assays can quickly and effectively screen and triage novel hits.

The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity in collaboration with Dr. Keith Elkon at the University of Washington, Seattle.  

The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway.

The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.

The newTranscreenercGAMPcGASAssay directly measures the productcGAMP, in acGASenzymatic reaction allowing researchers to screen vast compound libraries for modulators of the enzyme. The assay will be used to discover and develop new treatments for autoimmune diseases and cancer by strategically targeting thecGAS-STING pathway.

Methyltransferases have become a major focus of drug discovery for cancer and other diseases driven by epigenetic factors.  BellBrook Labs’ new, ultra-sensitive AptaFluor™ SAH Methyltransferase Assay eliminates cost and sensitivity barriers that are slowing the discovery of methyltransferase inhibitors.

New Target for Liver Fibrosis Using Transcreener GTPase Assay Platform

BellBrook Labs Launches New Turn Key Methyltransferase Assay Kit for Oncogenic Histone Methyltransferase EZH2.

BellBrook Labs Develops a TR-FRET Based Transcreener HTS Assay for Phosphodiesterases, Ligases, and Synthetases.